The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing

Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per a...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of gastroenterology & hepatology 2015, Vol.29 (1), p.46-48
Main Author: Shafran, Stephen D
Format: Article
Language:English
Subjects:
Antiviral drugs
Drug therapy
Genotype & phenotype
Health economics
Hepatitis
Original
Studies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per antiviral regimen is increasing, the cost per cure is decreasing, especially with interferon-free therapy. In a publicly funded health care system, the lowest cost per cure is a more valuable measure of value for public money than the cost per regimen.
ISSN:2291-2789
2291-2797
DOI:10.1155/2015/216395